Assembly Biosciences Ditches HBV Program, Cuts 45% Workforce
Ticker: ASMB · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: strategic-shift, layoffs, drug-discontinuation, pipeline-change
TL;DR
Assembly Bio is killing its Hep B drug and laying off nearly half its staff to focus on gut bugs. Cash saved.
AI Summary
Assembly Biosciences, Inc. announced on May 29, 2024, a strategic decision to discontinue its Hepatitis B virus (HBV) program, including its lead drug candidate vebicorvir. This move is part of a broader strategic realignment to focus on its microbiome-based therapies for infectious diseases. The company will also reduce its workforce by approximately 45% to conserve cash and extend its operating runway.
Why It Matters
This pivot away from a key drug program and significant layoffs indicate a major strategic shift for Assembly Biosciences, potentially impacting its future development pipeline and financial stability.
Risk Assessment
Risk Level: high — Discontinuing a drug program and significant workforce reduction signals substantial challenges and a high degree of uncertainty for the company's future prospects.
Key Numbers
- 45% — Workforce Reduction (Significant cost-saving measure and strategic realignment)
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Registrant
- vebicorvir (drug_candidate) — Lead Hepatitis B virus (HBV) drug candidate being discontinued
- Hepatitis B virus (HBV) (disease) — Program being discontinued
- May 29, 2024 (date) — Date of earliest event reported
- 45% (percentage) — Percentage of workforce reduction
FAQ
What is the primary reason for discontinuing the HBV program?
The company is discontinuing the HBV program as part of a strategic realignment to focus on its microbiome-based therapies for infectious diseases.
What specific drug candidate is affected by this decision?
The lead drug candidate vebicorvir, which was part of the HBV program, is being discontinued.
What is the expected impact of the workforce reduction?
The company expects to reduce its workforce by approximately 45%, which is intended to conserve cash and extend its operating runway.
What is the new strategic focus for Assembly Biosciences?
The company is shifting its focus to its microbiome-based therapies for infectious diseases.
When was the earliest event reported in this filing?
The earliest event reported was on May 29, 2024.
Filing Stats: 1,212 words · 5 min read · ~4 pages · Grade level 8.8 · Accepted 2024-06-03 16:05:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
Filing Documents
- asmb-20240529.htm (8-K) — 82KB
- asmb-ex10_1.htm (EX-10.1) — 162KB
- asmb-ex10_2.htm (EX-10.2) — 53KB
- 0000950170-24-067951.txt ( ) — 458KB
- asmb-20240529.xsd (EX-101.SCH) — 30KB
- asmb-20240529_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 29, 2024, the matters listed below were submitted to a vote of the Company's stockholders at the Annual Meeting through the solicitation of proxies. Detailed descriptions of each of the proposals are included in the Proxy Statement. The results of the stockholders' votes are as follows: 1. William R. Ringo, Jr., Anthony E. Altig, Tomas Cihlar, Ph.D., Gina Consylman, Robert D. Cook II, Sir Michael Houghton, Ph.D., Lisa R. Johnson-Pratt, M.D., Susan Mahony, Ph.D., John G. McHutchison, A.O., M.D. and Jason A. Okazaki were each elected to serve on the Company's Board of Directors until the Company's 2025 annual meeting of stockholders and until their successors are duly elected and qualified. Director Nominee Votes For Votes Against Abstain Broker Non-Votes William R. Ringo, Jr. 2,357,609 81,571 6,456 657,217 Anthony E. Altig 2,368,877 73,597 3,162 657,217 Tomas Cihlar, Ph.D. 2,396,763 46,054 2,819 657,217 Gina Consylman 2,423,143 19,328 3,165 657,217 Robert D. Cook II 2,398,024 44,448 3,164 657,217 Sir Michael Houghton, Ph.D. 2,383,382 19,194 43,060 657,217 Lisa R. Johnson-Pratt, M.D. 2,370,787 29,960 44,889 657,217 Susan Mahony, Ph.D. 2,422,878 19,937 2,821 657,217 John G. McHutchison, A.O., M.D. 2,398,440 46,203 993 657,217 Jason A. Okazaki 2,433,188 11,256 1,192 657,217 2. The stockholders approved, on a non-binding advisory basis, the Company's named executive officers' compensation disclosed in the Proxy Statement. Votes For Votes Against Abstain Broker Non-Votes 2,364,369 35,903 45,364 657,217 3. The stockholders voted, on a non-binding advisory basis, on the frequency of future advisory votes to approve the Company's named executive officers' compensation. Consistent with a majority of the votes cast with respect to this proposal and the recommendation of the Bo
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan. 10.2 Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: June 3, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 3